Figures and Tables

From the following article:

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Cornelia M. Ulrich, Jeannette Bigler & John D. Potter

Nature Reviews Cancer 6, 130-140 (February 2006)

doi:10.1038/nrc1801

Figure 1 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Figure 1

Inflammation and carcinogenesis.

Figure 2 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Figure 2

NSAIDs, COX inhibition and prostaglandins.

Figure 3 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Figure 3

NSAIDs and non-COX targets.

Figure 4 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Figure 4

NSAID metabolism and excretion.

Figure 5 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Figure 5

NSAIDs and pharmacogenetic effects.

Table 1 - Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Table 1

NSAIDs, COX inhibition and clinical trials for cancer chemoprevention